Document Detail


Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
MedLine Citation:
PMID:  16504919     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Autoimmune mucocutaneous blistering diseases (AMBD) are an interesting group of rare diseases that affect the mucous membranes and the skin and are frequently or potentially fatal. The clinical presentation is significantly variable, as is the course and prognosis. The immunopathology is well characterized and the target antigens to which the autoantibodies are directed have been studied by various investigators. A significant majority of the patients respond to conventional therapy, which consists of high-dose long-term systemic corticosteroids and immunosuppressive agents. This treatment program has significantly improved the prognosis in many patients. In such patients, significant side effects of the drugs may appear and produce a very poor quality of life. In patients with progressive diseases, especially those with mucous membrane pemphigoid, the significant sequela; such as blindness, aphonia, and stenosis of the anal and vaginal canals can occur. In several patients treated with conventional immunosuppressive therapy, death occurs as a consequence of prolonged immune suppression leading to opportunistic infections. In this manuscript, the published data on the use of immunoglobulins intravenous (IGIV) in patients with AMBD is presented. The most important features of IGIV in patients with AMBD are: 1) the ability to clinically control the disease; 2) the ability to induce and maintain a long-term clinical remission; 3) a lower incidence of side effects; and 4) a higher quality of life. The important characteristic of the IGIV therapy in the AMBD is two-fold. First, the therapy, when given according to a published protocol, produces a lasting and long-term clinical remission, rather than a temporary arrest of the disease. Second, the therapy, as described in the protocol, has a very definitive endpoint. Consequently, once the patients are treated and go into long-term remission, the therapy is no longer required. The significant positive results obtained with IGIV are to a large extent also due to the associated aggressive topical therapy that was used and the frequent use of sublesional injections with triamcinolone. The rapid and early detection of cutaneous and mucosal infections and their treatment with systemic antibiotics is also a very important feature of IGIV therapy. When patients are under long-term conventional therapy, the infections are often not detected because they lack the ability to mount signs of inflammation. It is also becoming increasingly clear for patients to have a successful outcome, in treatment with IGIV therapy, it is critical that the physician spends a significant amount of time with each patient, monitor the therapy closely, and be familiar with the overall health of the patient. It is also best if the therapies are instituted by a physician who has significant interest and experience in blistering diseases and IGIV therapy.
Authors:
A Razzaque Ahmed
Related Documents :
17584689 - Utility of t-wave alternans in congestive heart failure.
11737739 - Sotalol in treatment of pediatric cardiac arrhythmias.
17587719 - A prospective study on the risk-stratification for patients with non-sustained ventricu...
3875989 - Automatic implantable cardioverter-defibrillator: appearance and complications.
23607089 - Fish detection of pml-rara fusion in ins(15;17) acute promyelocytic leukaemia depends o...
18679529 - Malignant arrhythmia in apical ballooning syndrome: risk factors and outcomes.
2249489 - Esophageal motility in an adult with a congenital h-type tracheoesophageal fistula.
22033789 - Evaluation of right ventricular function in patients with a previous episode of pulmona...
18716489 - Hyperthyroidism as a cause of autonomic dysreflexia.
Publication Detail:
Type:  Journal Article; Review     Date:  2005-12-13
Journal Detail:
Title:  International immunopharmacology     Volume:  6     ISSN:  1567-5769     ISO Abbreviation:  Int. Immunopharmacol.     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-02-28     Completed Date:  2006-04-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100965259     Medline TA:  Int Immunopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  557-78     Citation Subset:  IM    
Affiliation:
Center for Blistering Diseases, Department of Medicine, New England Baptist Hospital, Boston, MA 02120, USA. arahmedmd@msn.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Cortex Hormones / therapeutic use
Autoimmune Diseases / epidemiology,  pathology,  therapy*
Combined Modality Therapy
Humans
Immunization, Passive*
Immunoglobulins, Intravenous*
Immunosuppressive Agents / adverse effects,  therapeutic use
Pemphigoid, Bullous / pathology,  therapy
Skin Diseases / epidemiology,  pathology,  therapy*
Chemical
Reg. No./Substance:
0/Adrenal Cortex Hormones; 0/Immunoglobulins, Intravenous; 0/Immunosuppressive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
Next Document:  Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, ...